Currently, two clinical trials are being undertaken to test whether the GSK3β inhibitor LY2090314 (Eli Lily) enhances the efficacy of established chemotherapeutic agents for advanced solid cancers (http://clinicaltrials.gov/ct2/show/study/NCT01287520) and leukemia (http://clinicaltrials.gov/ct2/show/study/NCT01214603). The gene discussed is GSK3B; the disease is leukemia.